Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review
Human research record. Advances in therapy, 2018.
- Human
- 2018
Authorship
Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.
Source: the abstract of PMID 30414051. Checked Verification: Evidence verified by machine against declared source
This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.
Evidence verified by machine against declared source
Key facts
- Design
- Not reported
- System
- Human
- Scale
- Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
- Comparator
- Present
- Journal
- Advances in therapy
- Year
- 2018
- PMID
- 30414051
- Verification
- Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
- Full-text availability
- Abstract only
Technical summary
Research question
The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH.
Study design
One of the limitations of this study was the retrospective design.
Participants or experimental system
Aneurysmal SAH patients who had their aneurysm obliterated at our institution from 2007 to 2016 were retrospectively studied.
Study scale
Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
Intervention or exposure
Cerebrolysin was administered at daily doses of 30 ml for at least 3 days.
Comparator
Patients received Cerebrolysin treatment or standard care only (control group).
Outcomes examined
SAH sum score (0–30) was calculated as the mean of the Hijdra score, which is the sum of the amount of blood in ten cistern or fissure points (0–3 each).
Key findings
In good-grade patients (N = 216), clinical outcomes and mortality did not differ significantly between the control and Cerebrolysin groups.
Not reported in the declared source: Methods.
Limitations and uncertainty
Further studies are needed to confirm our results.
Cite
Cite the study
Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review
Y. Park, H. Yi, Kyu-Sun Choi, Young-Jun Lee, Dong-won Kim, S. Kwon. Advances in therapy. 2018. PMID 30414051. DOI 10.1007/
The study and its abstract belong to their authors and publisher. Cite them for anything the study found.
Report an error
If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.
The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.
The report form runs in the interactive page. Open this record with scripts enabled to send a report.
Corrections on this record
No correction has been recorded for this record.
Method sheet
No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.